Indeed, the growing body of evidence pointing to IFNγ as a therapeutic target in primary and secondary HLH, led to clinical trials with emapalumab, an IFNγ neutralizing antibody, in patients with primary HLH or with MAS during sJIA [26, 27]. Here, IFNG is linked to hemophagocytic syndrome.